KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases $235,500.00 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) major shareholder Venrock Healthcare Capital Par purchased 25,000 shares of the business’s stock in a transaction on Wednesday, April 9th. The shares were bought at an average price of $9.42 per share, for a total transaction of $235,500.00. Following the acquisition, the insider now owns 5,303,985 shares in the company, valued at $49,963,538.70. This trade represents a 0.47 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Wednesday, February 12th, Venrock Healthcare Capital Par bought 100,000 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average price of $9.23 per share, for a total transaction of $923,000.00.
• On Monday, February 10th, Venrock Healthcare Capital Par purchased 4,137 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average price of $9.14 per share, with a total value of $37,812.18.
• On Friday, February 7th, Venrock Healthcare Capital Par acquired 73,649 shares of KalVista Pharmaceuticals stock. The stock was purchased at an average cost of $9.29 per share, for a total transaction of $684,199.21.
• On Monday, February 3rd, Venrock Healthcare Capital Par acquired 14,562 shares of KalVista Pharmaceuticals stock. The shares were purchased at an average cost of $9.22 per share, with a total value of $134,261.64.
• On Thursday, January 30th, Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock. The stock was acquired at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Trading Up 9.0 %

Shares of KalVista Pharmaceuticals stock traded up $0.95 during trading on Friday, reaching $11.49. The company’s stock had a trading volume of 683,343 shares, compared to its average volume of 400,900. The firm has a market cap of $571.24 million, a PE ratio of -3.16 and a beta of 0.39. The company has a 50-day moving average price of $11.07 and a two-hundred day moving average price of $10.30. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. GAMMA Investing LLC grew its holdings in shares of KalVista Pharmaceuticals by 567.3% during the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock worth $51,000 after buying an additional 3,767 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in KalVista Pharmaceuticals during the 4th quarter worth approximately $44,000. Tower Research Capital LLC TRC grew its stake in shares of KalVista Pharmaceuticals by 666.9% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after purchasing an additional 5,502 shares during the last quarter. Legal & General Group Plc increased its holdings in shares of KalVista Pharmaceuticals by 22.5% in the fourth quarter. Legal & General Group Plc now owns 8,144 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 1,494 shares during the period. Finally, Martin Worley Group acquired a new position in shares of KalVista Pharmaceuticals in the fourth quarter valued at approximately $86,000.

Analysts Set New Price Targets

Several research analysts have recently issued reports on KALV shares. Jones Trading reaffirmed a “buy” rating and set a $30.00 price objective on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research report on Tuesday. Finally, Bank of America initiated coverage on shares of KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 price target for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $24.83.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).